Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures grows, but more slowly than its trailing trend

Q1 FY2026 capital expenditures of $91K (cash outflow) rose 152.8% year over year, behind the +536.1% change in trailing-twelve-month capital expenditures. Sequentially, it rose 264.0% from the prior quarter. Over 3 fiscal years it compounded at -13.5% a year.

Context

  • Capital expenditures increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +152.8% toward the trailing-twelve-month pace of +536.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$91K+264.0% QoQ
Last fiscal yearDec 2025
-$174K— YoY
LTMMar 2026
-$229K+536.1% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+152.8%——
1 year———
3-year CAGR-13.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(174K) USD
Year-over-year change
—

Capital Expenditures vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +536.1% is the highest of 7, against a peer median of -66.1%.
  • Over three fiscal years its annual growth of -13.5% compares with a peer median of -50.3%.
CRVS Competitors
Capital Expenditures for CRVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M USD-37.7%-19.2%1.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$1M USD-66.7%-30.7%0.9%
NKTRNektar TherapeuticsLTM Jun 2026$262K USD-77.5%-68.9%0.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$229K USD+536.1%-13.5%—
IPHAInnate Pharma S.A.FY2025€134.47K EUR-65.6%-50.7%4.8%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$101K USD-67.8%-49.8%0.3%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$89K USD+43.5%-51.0%—
ADAGAdagene Inc.LTM Jun 2024$12.55K USD—-70.9%1.5%
CGENCompugen Ltd.LTM Dec 2025$0 USD—-14.3%0.0%
CHRSCoherus Oncology, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CRVS) —-66.1%-50.3%0.7%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Depreciation & Amortization460K367K151K85K105K
Deferred Income Tax00000
Stock-Based Compensation4.23M2.69M2.15M3M5.33M
Change in Working Capital(3.24M)1.41M(3.59M)(1.65M)3.58M
Accounts Receivables(507K)(81K)562K(49K)38K
Inventory00000
Accounts Payables(1.9M)411K(451K)1.06M(91K)
Other Working Capital(827K)1.08M(3.71M)(2.66M)3.63M
Other Non-Cash Items5.07M9.81M4.39M35.43M(26.53M)
Operating Cash Flow(36.72M)(27.02M)(23.94M)(25.42M)(32.8M)
Capital Expenditures(5K)(269K)(34K)0(174K)
Acquisitions (Net)(21.57K)22K05K0
Purchases of Investments(9.36M)(66.19M)(47.05M)(70.12M)(91.75M)
Sales of Investments30.92M43.16M62.62M42.63M84.13M
Other Investing Activities21.57K0000
Investing Cash Flow21.56M(23.28M)15.54M(27.48M)(7.8M)
Debt Repayment00000
Common Stock Issued60.94M07.84M16.41M36.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.22M012K32.62M0
Financing Cash Flow62.16M07.86M49.03M36.43M
Effect of Forex Changes00000
Net Change in Cash47M(50.3M)(539K)(3.88M)(4.16M)
Free Cash Flow(36.72M)(27.29M)(23.97M)(25.42M)(32.97M)

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.